- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Patent holdings for IPC class A61K 31/437
Total number of patents in this class: 10924
10-year publication summary
|
710
|
763
|
795
|
797
|
763
|
787
|
726
|
814
|
822
|
562
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4748 |
170 |
| Incyte Corporation | 1066 |
140 |
| F. Hoffmann-La Roche AG | 7815 |
126 |
| Genentech, Inc. | 4115 |
122 |
| Takeda Pharmaceutical Company Limited | 2712 |
120 |
| Boehringer Ingelheim International GmbH | 4483 |
106 |
| Janssen Pharmaceutica N.V. | 3161 |
104 |
| Merck Sharp & Dohme LLC | 3736 |
104 |
| Novartis AG | 10178 |
103 |
| Gilead Sciences, Inc. | 2231 |
99 |
| Merck Patent GmbH | 5735 |
85 |
| Hoffmann-La Roche Inc. | 3815 |
76 |
| The Regents of the University of California | 20802 |
74 |
| Pfizer Inc. | 3404 |
67 |
| Bayer Pharma AG | 1010 |
66 |
| Abbvie Inc. | 1822 |
64 |
| Dana-Farber Cancer Institute, Inc. | 2668 |
64 |
| Plexxikon Inc. | 146 |
59 |
| Taisho Pharmaceutical Co., Ltd. | 850 |
59 |
| AstraZeneca AB | 2824 |
55 |
| Other owners | 9061 |